What is BPC-157? What it does, benefits and what the evidence shows

BPC-157 is a synthetic 15-amino-acid peptide, a partial sequence of a larger protein first isolated from human gastric juice by researchers in Zagreb, Croatia, and published in 1993. It has never been approved by FDA for any use. Almost all research on BPC-157 is in rats and mice, on tendon, ligament, muscle, bone and gut healing. Only three small human studies have been published, enrolling 2, 17 and 12 people, and none was a controlled efficacy trial.

What BPC-157 is and how it works

The name stands for "Body Protection Compound." Predrag Sikiric and colleagues in Zagreb, Croatia first described it as a peptide isolated from gastric juice with protective effects, publishing in the Journal of Physiology, Paris in 1993 (Sikiric et al. 1993, cited in Inflammopharmacology, 2025, via PMC). It's manufactured by chemical synthesis rather than extracted from gastric juice, and researchers describe it as unusually stable in gastric juice and resistant to enzymatic degradation compared with most peptides — a property some researchers have speculated may relate to the four proline residues in its 15-amino-acid sequence — which is part of why it's been studied as an oral candidate in animal models rather than only injectable.

Mechanistically, animal and cell studies attribute BPC-157's effects to several overlapping pathways: it promotes angiogenesis (new blood vessel growth) partly through VEGFR2 and nitric-oxide signaling via the Akt-eNOS pathway, activates ERK1/2 signaling in fibroblasts, and appears to shift local macrophage behavior toward a repair-oriented state rather than a purely inflammatory one (narrative review, PMC, 2026). In rat tendon fibroblasts specifically, it dose- and time-dependently increases expression of the growth hormone receptor (Molecules, 2014), and it speeds outgrowth of fibroblasts from tendon explants and their migration in vitro (Journal of Applied Physiology, 2011). One notable feature researchers flag: in rats, the angiogenic and anti-inflammatory effects appear to persist for weeks to months, well past the time the peptide itself would still be present in the body — a gap between exposure and effect that isn't fully explained.

None of this describes what happens when a person takes it. It describes what happens in cultured cells and in rodents.

What people use it for

What the research actually shows

Tendon, ligament and muscle healing — rats only

This is the largest single body of BPC-157 research, and all of it we could verify is in rats. In one frequently cited laboratory study, researchers used tendon explants and tendon fibroblasts taken from rat Achilles tendon (no live animals were injured or treated) and found that BPC-157 accelerated outgrowth of the explants, increased cell survival under oxidative stress, and increased cell migration in a dose-dependent way, likely through the FAK-paxillin pathway (J. Appl. Physiol., 2011). A separate study in cultured rat tendon fibroblasts found that BPC-157 increased growth hormone receptor expression at both the mRNA and protein level (Molecules, 2014). A 2019 review reports consistently positive healing effects across tendon, ligament and skeletal muscle injury models, but notes most studies used small rodent models and efficacy in humans is unconfirmed (PubMed, 2019). We found no published human trial testing BPC-157 for tendon or ligament repair with any outcome measure — imaging, strength testing, or otherwise.

Gut and gastrointestinal healing — the compound's original context, still rats

BPC-157 was first studied as a gastric-protective substance, and a large share of the Sikiric group's published work is in that area: rat models of gastric ulcer and, notably, intestinal anastomosis healing (surgically rejoined bowel). One such study, whose title itself notes the compound was "in trials for inflammatory bowel disease" under earlier development names (PL-10, PLD-116, PL14736) through the Croatian pharmaceutical company Pliva, found that BPC-157 improved healing parameters — reduced edema and necrosis, increased granulation tissue and collagen formation — after ileoileal anastomosis surgery in rats (PubMed, 2007). The title referencing "trials for inflammatory bowel disease" reflects that a related development program existed; we could not locate a published, peer-reviewed human IBD trial result to verify what, if anything, came of it, so we're not making any claim about human gut outcomes here.

Human data: three small studies, no controlled efficacy trial

A 2025 narrative review counts three published human studies, and none of them tested whether BPC-157 works for anything in a controlled way (McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025):

• A 2025 pilot safety study gave intravenous BPC-157 to two healthy adults — a 58-year-old man and a 68-year-old woman — starting at a lower amount on day one and a higher one on day two. The infusions were well tolerated with no adverse effects reported, and blood work covering heart, liver, kidney, thyroid and glucose markers showed no measurable changes (Alternative Therapies in Health and Medicine, Sept/Oct 2025, via PubMed). That's a safety signal in two people over two days, not evidence the peptide does anything therapeutic.
• A 2021 retrospective chart review at one clinic covered 17 patients who'd had knee injections of BPC-157 (or BPC-157 combined with thymosin beta-4) for knee pain; 16 were reached for follow-up, and 14 of those 16 (87.5%) reported relief (Lee and Padgett, Alternative Therapies in Health and Medicine, 2021). There was no control group and no consistent diagnosis across patients, which is exactly the kind of design that can't separate a real drug effect from placebo, natural improvement, or selection bias in which charts got reviewed.
• A 2024 pilot study treated 12 women with interstitial cystitis (a painful bladder condition) with BPC-157 injected into the bladder wall during a single procedure; 10 reported complete resolution of symptoms and the other 2 most of them (Lee et al., Alternative Therapies in Health and Medicine, 2024). It had no control group, and a condition known for strong placebo responses makes an uncontrolled result especially hard to read.

A separate Phase I safety trial of an oral BPC-157 formulation was registered in 2015, but its status is listed as unknown and no results have been posted (ClinicalTrials.gov NCT02637284).

That's the entire published human evidence base. There is no human trial demonstrating BPC-157 improves tendon healing, athletic recovery, gut symptoms, or anything else — the animal literature and the human literature are, right now, almost entirely separate bodies of evidence.

Side effects and risks

Because there's essentially no human safety data beyond two people over two days, most of what's known about risk comes from theory and from animal toxicology, not from monitoring real users over time.

In rat and other animal toxicology work, researchers have reported they were unable to identify a minimum toxic dose or a lethal amount, with no teratogenic, genotoxic, anaphylactic or local toxic effects observed at the amounts tested — a reassuring animal signal, but not a substitute for human data. The main theoretical concern raised in the scientific literature is that BPC-157's angiogenic effect (growing new blood vessels) could, in principle, support tumor growth if a tumor were present; researchers who study it note this is unresolved and cite conflicting lab evidence that BPC-157 can also inhibit uncontrolled cell proliferation and counteract VEGF-driven tumor growth in some models (narrative review, PMC). Nobody has resolved this either way in humans, which is the honest state of it.

Two more concrete facts, not theoretical. First, the World Anti-Doping Agency named BPC-157 by name on its 2022 Prohibited List, under section S0 for non-approved substances (World Rugby summary of WADA's announcement; USADA). Second, on the regulatory side, BPC-157 sat in Category 2 of FDA's interim list of bulk substances nominated for compounding — a category the agency reserves for substances it has flagged with significant safety concerns — from 2023 until April 15, 2026, when FDA announced its removal because the nomination had been withdrawn. That removal is not approval and does not make BPC-157 eligible for compounding: it stays outside the categories the agency currently allows (Frier Levitt, April 16, 2026). At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee then voted to recommend adding BPC-157, along with KPV, TB-500, MOTS-c, Epitalon and Semax, to the 503A bulks list that licensed compounding pharmacies can draw on. The BPC-157 vote was 8 to 6 with one abstention, and FDA's own staff reviewers had recommended against adding these substances (AJMC, July 31, 2026). That vote is non-binding: the Secretary of Health and Human Services still has to approve any addition, and pharmacies can't compound these peptides until the final rule is in place (NCPA, July 31, 2026). If it goes through, it would create a prescription route through licensed pharmacies; it would not make BPC-157 an FDA-approved drug, which it has never been for any indication.

On the grey-market side specifically, our data shows a real quality problem that has nothing to do with the biology: overfill. Of 41 BPC-157 vials in our database, 34 had both a label amount and a measured amount, and the median measured amount ran 17.8% over label — 2 of those 34 landed within ±5% of label, while 13 measured more than 20% over and 1 measured more than 50% over. Purity, separately, was mostly strong (33 of 38 vials with a result at 99%+) but 2 vials came in under 95% pure. Altogether 3 of the 41 tested vials failed our definition (empty, under 95% pure, more than 20% under label, or more than 50% over). None of that tells you anything about whether the compound works — it tells you what's actually in the vial versus what the label claims.

What the lab tests show

As of September 30, 2026, our database includes 41 BPC-157 vials from 14 vendors, drawn from 31 lab reports dated November 2024 through August 2026. As of September 29, 2026, the overfill pattern above (median +17.8% over label) was the standout number for this compound — a heavier skew than most other peptides in our data, where modest overfill is common but rarely this pronounced. Endotoxin testing is thin (8 results among the 202 endotoxin tests in our broader database as of September 29, 2026), so we're not drawing conclusions about it here beyond noting it's rarely ordered for this compound.

That's a small sample, and a single vendor with several vials can move these numbers noticeably — treat them as a snapshot, not a settled verdict. Here's how the ranked vendors for BPC-157 look right now; the table shows current verdicts and flags any vendor whose failed-vial rate is above 5%. Ranked isn't automatically good, and for a compound with 41 total vials tested, this table may be short:

Buying smarter

If you're evaluating a specific vendor's BPC-157, check their full record on our BPC-157 results page rather than relying on a handful of reports — a vendor needs five or more lab reports before we rank them, and the number of reports behind a score matters as much as the score itself. Whatever COA a vendor posts is worth treating as a starting point, not proof: verify it against how to read a peptide COA, and check for the red flags in fake peptide COAs before trusting a number you didn't see tested yourself.

Given how common overfill is in this compound's data, a quantity test on your own vial is arguably more informative than a purity retest — purity looked fine in the large majority of reports we have, but dose-versus-label is where the spread showed up. How to get a peptide tested walks through ordering independent identity, purity and quantity testing from a lab, and when it's worth adding endotoxin testing given how rarely it's been checked for this specific compound so far.

If your own report comes back with a fail, stop using that batch, tell anyone else who bought from the same run, bring the report to the vendor, and submit it to VendorVerify so the next buyer checking that vendor's BPC-157 record has one more data point than you did.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice; BPC-157 is sold for research use only and has not been evaluated by FDA for safety or effectiveness in humans.